scholarly journals Introducing seasonal influenza vaccine in low‐income countries: an adverse events following immunization survey in the Lao People's Democratic Republic

2015 ◽  
Vol 9 (2) ◽  
pp. 94-98 ◽  
Author(s):  
Manilay Phengxay ◽  
Sara A. Mirza ◽  
Rita Reyburn ◽  
Anonh Xeuatvongsa ◽  
Christian Winter ◽  
...  
Keyword(s):  
Adverse Events ◽  
Influenza Vaccine ◽  
Low Income ◽  
Seasonal Influenza ◽  
Democratic Republic ◽  
Low Income Countries ◽  
Seasonal Influenza Vaccine ◽  
Lao People’S Democratic Republic ◽  
Lao People's Democratic Republic

scholarly journals Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia

2017 ◽  
Vol 22 (20) ◽  
Author(s):  
Hazel J Clothier ◽  
Nigel Crawford ◽  
Melissa A Russell ◽  
Jim P Buttery
Keyword(s):  
Adverse Events ◽  
Confidence Interval ◽  
Influenza Vaccine ◽  
Allergic Reaction ◽  
Seasonal Influenza ◽  
Vaccine Safety ◽  
Clinical Severity ◽  
Influenza Vaccines ◽  
Seasonal Influenza Vaccine ◽  
Initial Investigation

Australia was alerted to a possible increase in allergy-related adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88–1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14­– 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance.

scholarly journals Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

2014 ◽  
Vol 8 (09) ◽  
pp. 1160-1168 ◽  
Author(s):  
Adib Rodriguez Solares ◽  
Carlos Grazioso Aragon ◽  
Rodolfo Urruela Pivaral ◽  
David Prado-Cohrs ◽  
Victor Sales-Carmona ◽  
...  
Keyword(s):  
Adverse Events ◽  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Antibody Responses ◽  
Entire Study ◽  
Seasonal Influenza Vaccine ◽  
Adjuvanted Vaccine ◽  
Trivalent Influenza Vaccine ◽  
Antibody Titers

Introduction: The efficacy of non-adjuvanted seasonal influenza vaccine in young children is considered to be suboptimal.  This study compared the safety and immunogenicity profiles of MF59-adjuvanted, trivalent, influenza vaccine (ATIV) and non-adjuvanted, trivalent, influenza vaccine (TIV) in Guatemalan children (N = 360) between 6 and < 60 months of age. Methodology: Children received two doses of ATIV or TIV administered four weeks apart. Solicited adverse reactions were recorded for seven days after each vaccination. Serious adverse events were recorded throughout the entire study period. Antibody responses were assessed by hemagglutination inhibition (HI) assay at baseline, four weeks after administration of the first vaccine dose, and three weeks after administration of the second dose. Results: Both ATIV and TIV were well tolerated, with similar rates of solicited reactions and adverse events observed in response to both vaccines. MF59-adjuvanted vaccine induced considerably higher antibody titers than did TIV. After two doses, the B strain-specific antibody response to TIV was insufficient to meet the Center for Biologics Evaluation and Research (CBER) licensure criterion for seroprotection, whereas responses to the MF59-adjuvanted vaccine met the seroprotection criterion against all three strains. Cross-reactive antibody responses to MF59-adjuvanted vaccine met the CBER seroprotection criterion against all three strains after two doses; B strain-specific heterologous responses to non-adjuvanted TIV were inadequate. Conclusions: The MF59-adjuvanted seasonal influenza vaccine was well-tolerated and highly immunogenic in children 6 to < 60 months of age, inducing seroprotective antibody titers against both the vaccine strains and antigenically distinct heterologous strains.

scholarly journals Healthcare Workers’ Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 465
Author(s):  
Leena R. Baghdadi ◽  
Shatha G. Alghaihb ◽  
Alanoud A. Abuhaimed ◽  
Dania M. Alkelabi ◽  
Rawan S. Alqahtani
Keyword(s):  
Saudi Arabia ◽  
Influenza Vaccine ◽  
Work Experience ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Seasonal Influenza Vaccine ◽  
History Of

In 2019, a novel severe acute respiratory syndrome (SARS-CoV-2 (COVID-19)) caused a global pandemic. There was an urgent need to develop a vaccine against COVID-19 to reduce its spread and economic burden. The main objective of this study was to understand the attitudes and concerns of healthcare workers (HCWs) towards the upcoming COVID-19 vaccine, whether their decision was influenced by their history of taking the seasonal influenza vaccine, and factors that influence the acceptance of the upcoming COVID-19 vaccine. This was a cross-sectional study conducted in Riyadh, Saudi Arabia. We selected and surveyed 356 HCWs via an electronic self-administered questionnaire. A total of 61.16% of HCWs were willing to receive the COVID-19 vaccine, and 55.9% of them had received the seasonal influenza vaccine in the preceding year (2019–2020). The strongest predictors for taking the COVID-19 vaccine were the HCWs’ belief that the COVID-19 vaccine would be safe, needed even for healthy people, that all HCWs should be vaccinated against COVID-19, and that HCWs will have time to take the vaccine. Being female, being middle aged, having <5 years of work experience, having no fear of injections, and being a non-smoker were predictive factors for taking the upcoming COVID-19 vaccine. No associations were found between the intention to take the COVID-19 vaccine and a history of taking the seasonal influenza vaccine.

scholarly journals A North–South-South partnership in higher education to develop health research capacity in the Democratic Republic of the Congo: the challenge of finding a common language

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Christiane Horwood ◽  
Sphindile Mapumulo ◽  
Lyn Haskins ◽  
Vaughn John ◽  
Silondile Luthuli ◽  
...  
Keyword(s):  
Higher Education ◽  
Low Income ◽  
Health Research ◽  
Democratic Republic ◽  
Academic Staff ◽  
Research Capacity ◽  
Nutritional Epidemiology ◽  
Low Income Countries ◽  
Republic Of The Congo ◽  
English Speaking

Abstract Background Globally, increasing numbers of higher education institutions (HEIs) in non-English-speaking countries have adopted English as a medium of instruction (EMI), because of the perception that this provides opportunities to attract high-calibre students and academic staff, and engage with the international research community. We report an evaluation of a North–South-South collaboration to develop health research capacity in the Democratic Republic of the Congo (DRC) by establishing a postgraduate programme in nutritional epidemiology at the Kinshasa School of Public Health (KSPH), where EMI was adopted. We report experiences and perceptions of stakeholders, facilitators and students about using EMI. Methods In-depth qualitative interviews were conducted between October and December 2019 among convenience sampled stakeholders (8), facilitators (11) and students (12) involved in the programme from all three partner institutions (University of Kinshasa; University of KwaZulu-Natal, South Africa; University of Bergen, Norway). Interviews were conducted in participants’ language of preference (English or French), audio-recorded, transcribed verbatim and translated into English when required. Analysis employed a thematic approach. Results Most participants viewed EMI positively, reporting that studying in English created opportunities to access relevant literature, improve interactions with the scientific community and advance their careers. As a result of adopting EMI, some students had opportunities to present research findings at international conferences and publish their research in English. English-speaking researchers from partner institutions were able to participate in supervision of students’ research. However, inadequate English competency, particularly among students, was challenging, with some students reporting being unable to understand or interact in class, which negatively affected their academic performance. Further, EMI created barriers at KSPH among academic staff who were not proficient in English, leading to poor participation among non-English-speaking staff and lack of integration with other postgraduate programmes. Participants suggested additional English language support for EMI. Conclusion Partnerships between HEIs could be a powerful tool to develop research capacity in low-income countries in line with United Nations Sustainable Development Goals. EMI could be a solution to language barriers faced by many such partnerships, but wide-ranging support to develop English proficiency among staff and students is essential to ensure that the challenges do not outweigh the benefits.

Sign in / Sign up

Export Citation Format

Share Document